FORT WORTH, Texas–(BUSINESS WIRE)–Alcon, the global leader in eye care, is teaming up with gold- and silver-medal winning gymnast Laurie Hernandez on a new campaign that encourages people to find inspiration to visualize and achieve their goals. The …
Ultra-Thin Probe Assesses Tissues Deep Within Lungs
Assessing the health of tissues deep inside the body is a major need and challenge in medicine. Imaging modalities such as MRI, CT, and ultrasound provide very little information about the composition and environment of tissues being examined. Now, researchers at the University of Edinburgh, Heriot-Watt University, and Bath University, all in the U (Read more...)
Ribomic’s wet AMD candidate shows positive phase 1/2a topline results
A single dose of RBM-007, an oligonucleotide-based aptamer with anti-FGF2 activity, showed positive topline results in a phase 1/2a clinical trial in wet age-related macular degeneration patients, according to a press release.RBM-007 (Ribomic) was well…
Resumen: RIBOMIC anuncia resultados positivos de la primera línea del ensayo clínico de fase 1/2a de RBM-007 (estudio SUSHI) en sujetos con degeneración macular húmeda relacionada con la edad
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., una compañía farmacéutica en etapa clínica especializada en terapias de aptámeros y cotizada en el Mothers Market de la Bolsa de Tokio (número de código: 4591), ha anunciado hoy los resultados positivos de primera…
Riassunto: RIBOMIC comunica i risultati principali positivi emersi dalla sperimentazione clinica di Fase I/IIa su RBM-007 (studio SUSHI) in soggetti affetti da degenerazione maculare umida dovuta all’invecchiamento
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., un’impresa farmaceutica operante nella fase clinica specializzata in terapie a base di aptameri e quotata presso il Mothers Market della Borsa di Tokyo (codice: 4591), ha comunicato oggi i risultati principali pos…
Samenvatting: RIBOMIC kondigt positieve toplijnresultaten aan van het fase-1/2a klinisch onderzoek van RBM-007 (SUSHI-studie) bij proefpersonen met natte leeftijdsgebonden maculaire degeneratie
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., een farmaceutisch bedrijf van het klinische stadium dat zich in aptamertherapie specialiseert en dat op de Mothers Market van de Beurs van Tokyo wordt verhandeld (Codenummer: 4591), kondigde vandaag positieve hoog…